|
N-Nitroso Metamizole Impurity C
|
|
4
|
374
|
May 13, 2026
|
|
QSAR Toolbox - Free software. Any experience?
|
|
20
|
2362
|
May 12, 2026
|
|
N-Nitroso Mefanaminc Acid
|
|
1
|
146
|
May 12, 2026
|
|
N-Nitroso Desethyl Amiodarone in Amiodarone HCl Tablets by LC-MS/MS Metodu
|
|
2
|
180
|
May 12, 2026
|
|
Development of an Efficient and Scalable Process for Preparing Timolol N-Nitrosamine Impurities B, C, E, H, I, J, and Their ADMET Evaluation -Pub
|
|
2
|
178
|
May 8, 2026
|
|
Diluent Selection for Nitrosamine Impurities
|
|
7
|
320
|
May 8, 2026
|
|
FDA-CDER and HESI | Nitrosamine Ames Data Review and Method Development Workshop
|
|
2
|
399
|
May 6, 2026
|
|
Generic Drugs Forum (GDF) 2026
|
|
17
|
839
|
May 5, 2026
|
|
Benchmark Dose (BMD) Modeling for Risk Assessment webinar
|
|
1
|
295
|
May 4, 2026
|
|
Adjusting the Preincubation Conditions to Enhance the Ames Test for Detecting the Mutagenicity of N‐Nitrosamines-Pub
|
|
2
|
167
|
May 1, 2026
|
|
Hunt for NDSRIs: Unveiling Hidden Threats with the Novel 15N-Enriched NAP Test-Pub
|
|
3
|
485
|
April 30, 2026
|
|
Early life exposure to N-nitrosamine drives genotoxicity, mutagenesis, and tumorigenesis in DNA repair-deficient mice -Pub
|
|
5
|
452
|
April 30, 2026
|
|
N-Nitroso dially amine estimation by LCMS
|
|
2
|
91
|
April 29, 2026
|
|
N-NO formation in 2-mercaptobenzothiazole
|
|
2
|
128
|
April 29, 2026
|
|
Something in the air−Unveiling the role of atmospheric nitrogen oxides in nitrosamine formation from amine-containing APIs: Mechanistic insights and risk assessment-Pub
|
|
2
|
418
|
April 28, 2026
|
|
Nitrosamine limit in the specification based on intermediate and accelerated stability condition results
|
|
4
|
225
|
April 28, 2026
|
|
How to overcome blank interference at NDBA
|
|
4
|
188
|
April 27, 2026
|
|
🇯🇵 Current Nitrosamine Landscape in Japan?
|
|
186
|
17557
|
April 26, 2026
|
|
Removal of nitrosamine analysis from the specification
|
|
3
|
241
|
April 24, 2026
|
|
Regulatory Flexibilities and Clarifications: Chemistry, Manufacturing and Control (CMC) Information for Original First in Human (FIH) Phase 1 INDs
|
|
0
|
218
|
April 23, 2026
|
|
Construction of a modified Arrhenius equation for predicting drug nitrosation in solid dosage form -Pub
|
|
4
|
1015
|
April 21, 2026
|
|
Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern -Pub
|
|
0
|
161
|
April 21, 2026
|
|
Kinetic reaction rates for nitrosamine formation using secondary amines pKa
|
|
3
|
356
|
April 21, 2026
|
|
About the amlodipine nitrosamines
|
|
3
|
233
|
April 21, 2026
|
|
EMA's Revision of the Acceptance Limit for N-Nitroso-N-desmethyl-diphenhydramine
|
|
4
|
463
|
April 20, 2026
|
|
Another Prazosin recall linked to N-nitroso-prazosin impurity C raises renewed concern for the finished product
|
|
8
|
610
|
April 20, 2026
|
|
Potential for Nitrosamines in Medical Device Combination Products - Letter to Industry(FDA)
|
|
4
|
204
|
April 20, 2026
|
|
Etelcalcetide Nitroamide – is this possible?
|
|
0
|
77
|
April 18, 2026
|
|
Maximum Daily Dose (MDD) of Cream Formulation
|
|
1
|
209
|
April 17, 2026
|
|
🇺🇸 FDA Workshop - Nitrosamine-driven Reformulation and Bioequivelance
|
|
1
|
249
|
April 17, 2026
|